Alicorn Pharmaceutical Co., Ltd

Alicorn Pharmaceutical Co., Ltd traces its history to 2015 as Jiangsu Alicorn Medical & Technology Co., Ltd, earning recognition as a National High-tech Enterprise in 2018 before reorganizing under its current name in 2021. The company operates three R&D centers — in Nanjing (process research and optimization of APIs, intermediates and solid/liquid dosage forms), Jiaxing (new molecular compound synthesis) and Anqing (under construction, for process scale-up and cost control) — alongside an Anqing manufacturing site with reactors from 500 to 5,000 liters capable of high-temperature, high-pressure, cryogenic and hydrogenation reactions, plus a separate facility for oral solid and external drug production. As a manufacturer, agent and service provider of prophylactic biological products and anti-infective drug APIs, the company offers CRO, CMO and CDMO contract services, holds several patents from its API and drug R&D work, and sells worldwide under a T/T-in-advance payment model, backed by internationally recognized approvals and an experienced R&D team.